Provided by Tiger Trade Technology Pte. Ltd.

Progress

43.42
-0.9400-2.12%
Post-market: 43.34-0.0804-0.19%18:43 EDT
Volume:331.72K
Turnover:14.53M
Market Cap:1.78B
PE:20.97
High:44.99
Open:44.17
Low:43.38
Close:44.36
52wk High:47.37
52wk Low:23.82
Shares:41.01M
Float Shares:40.11M
Volume Ratio:0.89
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.07
EPS(LYR):1.66
ROE:18.57%
ROA:4.89%
PB:3.52
PE(LYR):26.16

Loading ...

Waton Financial Highlights AlphaSchema Research Progress in Structured AI-Assisted Trading Signal Discovery

GlobeNewswire
·
Aug 10

US Equity Futures Mostly Flat Pre-Bell Amid Lack of Progress in Middle East Peace Negotiations

MT Newswires Live
·
Aug 10

China South City Updates Restructuring Progress as Trading Remains Suspended

TIPRANKS
·
Aug 10

Press Release: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b Plateau Clinical Trial Progress

Dow Jones
·
Aug 10

Recruit Holdings Likely Seeing Signs of Progress Through Sales Growth

Dow Jones
·
Aug 10

Kyushu Financial Group Updates Progress on Share Buyback Program

TIPRANKS
·
Aug 10

Is SolarEdge Technologies (SEDG) Undervalued As Q2 Results, Q3 Guidance, And Nexis Progress Land?

Simply Wall St.
·
Aug 10

Oaktree Specialty Lending Earnings Call Shows Cautious Progress

TIPRANKS
·
Aug 10

Mirrabooka Reports Progress on Ongoing On-Market Share Buy-Back

TIPRANKS
·
Aug 10

Molson Coors Earnings Call Balances Pain and Progress

TIPRANKS
·
Aug 09

UGI Corp Earnings Call Balances Pressure And Progress

TIPRANKS
·
Aug 09

MBIA Inc. Earnings Call: Runoff Progress, PREPA Risks

TIPRANKS
·
Aug 08

Lineage Cell Therapeutics Balances Progress and Risk

TIPRANKS
·
Aug 08

Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78

TIPRANKS
·
Aug 08

Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged

TIPRANKS
·
Aug 08

Analyst Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target Amid Pipeline Progress and Extended Cash Runway

TIPRANKS
·
Aug 08

Barzolvolimab’s Accelerated CSU Progress and Robust Market Backdrop Underpin Maintained Buy Rating and Unchanged $56 Price Target

TIPRANKS
·
Aug 08

Lyft's 2Q Results Show Progress but Raise Concerns over Core

Dow Jones
·
Aug 08

Becton, Dickinson's Fiscal Q3 Results Show Progress Amid Major Headwinds, RBC Says

MT Newswires Live
·
Aug 07

Lens Technology, Ju Teng Report Progress on Conditional Takeover Offer

TIPRANKS
·
Aug 07